The Elevated Employee Experience: Embracing Growth Through Continuous Learning with Mary McGrath

 

As a Training Specialist in A/R Services at ElevatePFS, Mary McGrath brings a passion for continuous learning and development to everything she does. Starting as a claims representative just over three years ago, Mary has grown into a role where she now helps others build the same skills and confidence that helped her succeed.

In a constantly evolving industry, Mary values the opportunity to learn alongside colleagues and adapt to change as a team. Her appreciation for shared knowledge and collaboration reflects ElevatePFS’s culture of continuous growth and support.

Through both teaching and continuous learning, Mary plays a key role in strengthening the organization, one training session at a time.

ElevatePFS is committed to developing talent from within, equipping team members with tools to thrive in a fast-paced, mission-driven environment. The company fosters a strong learning culture that supports both individual growth and collective success.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…